Literature DB >> 25087989

Are chargemaster rates for imaging studies lower in States that cap noneconomic damages (tort reform)?

Seth I Stein1, Jeffrey R Barry2, Saurabh Jha3.   

Abstract

PURPOSE: To determine whether chargemaster (a list of prices for common services and procedures set by individual hospitals) rates for diagnostic imaging were lower in states that cap awards for noneconomic damages (NED) than states with unlimited awards for medical negligence.
METHODS: We analyzed 2011 chargemaster data from the Centers for Medicare & Medicaid, pertaining to 6 ambulatory patient classifications specific to imaging. The dataset includes outpatient imaging facilities and hospitals in 49 states and the District of Columbia. The association between caps on NED and chargemaster rates for imaging in a sample of 15,218 data points was analyzed using linear regression and two-sample t tests assuming unequal variances.
RESULTS: In states that cap NED, the chargemaster rates were higher for the following modalities: Level II Echocardiogram without Contrast (mean charges: $2,015.60 versus $1,884.81, P = .0018); Level II Cardiac Imaging ($4,670.25 versus $4,398.58, P = .002); MRI & Magnetic Resonance Angiography without Contrast ($2,654.31 versus $2,526.74, P = .002); and Level III Diagnostic and Screening Ultrasound ($1,073.31 versus $1,027.32, P = .037). High charge-to-payment ratios were associated with states with the highest charges. There was a positive correlation between number of outpatient centers in the state and the average chargemaster rates for the state (mean chargemaster rate = 1727 + 0.79*Number of Outpatient Centers; R-squared = 0.23, P = .0004).
CONCLUSIONS: Chargemaster rates for select imaging services are not lower in states that have capped NED.
Copyright © 2014 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Tort reform; chargemaster; noneconomic damages; supply–demand

Mesh:

Year:  2014        PMID: 25087989     DOI: 10.1016/j.jacr.2014.03.010

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  1 in total

1.  The potential of targeting epigenetic regulators for the treatment of fibrotic cardiac diseases.

Authors:  Katherine B Schuetze; Keith A Koch; Timothy A McKinsey
Journal:  Future Med Chem       Date:  2016-08-24       Impact factor: 3.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.